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ABSTRACT
Purpose To study the self-association states of insulin degludec
and insulin aspart alone and combined in pharmaceutical formu-
lation and under conditions simulating the subcutaneous depot.
Methods Formulations weremade of 0.6 mM degludec at 3 and
5 Zn/6 insulin monomers, and 0.6 mM aspart (2 Zn/6 insulin
monomers). Self-association was assessed using size-exclusion
chromatography (SEC) monitored by UV and orthogonal
reverse-phase chromatography.
Results Simulating pharmaceutical formulation, degludec eluted
as dihexamers, whereas aspart eluted as hexamers and mono-
mers. Combining degludec at low zinc with aspart increased
dihexamer content, indicating hybrid hexamer formation. At high
zinc concentration, however, there was no evidence of this.
Simulating the subcutaneous depot by removing preservative,
degludec eluted as multihexamers and aspart as monomers.
Aspart was incorporated into the multihexamer structures when
combined with degludec at low zinc, but there was no such
interaction with high-zinc degludec. SEC using progressively dilut-
ed concentrations of phenol and m-cresol showed that dissocia-
tion of aspart into monomers occurs before the formation of
degludec multihexamers.
Conclusion Insulins degludec and aspart can be combined with-
out forming hybrid hexamers, but this combinability is dependent
on zinc and preservative concentration, and requires that
degludec is fully dihexameric before addition of aspart.
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INTRODUCTION
Insulin naturally associates into a hexameric structure in the
presence of zinc ions, thought to be an adaptation for efficient
storage within pancreatic beta-cell vesicles [1]. Upon secretion
into the circulation, dilution causes the insulin hexamers to
quickly dissociate into dimers and the biologically active
monomers. In normal physiology, insulin secretion is closely
regulated, typically presenting as a slow and relatively steady
‘basal’ rate, periodically supplemented by greatly increased
peaks of secretion in response to nutrient ingestion [2].
While self-association of insulin is physiologically benefi-
cial, it poses problems for subcutaneous injection therapy for
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diabetes. Hexamers are relatively large structures that do not
diffuse across capillary membranes as readily as monomers
do, and to provide a therapeutic insulin dose in a tolerable
injection volume requires insulin to be formulated at concen-
trations at which it is hexameric [3]. This means that a
subcutaneous depot is formed in which dilution occurs slowly,
hence the dissociation of hexamers and absorption of insulin
into the circulation is retarded, rising to and falling from a
peak over a period of a few hours. The resultant pharmaco-
kinetic (PK) profile resembles neither natural basal insulin
secretion nor the prandial response [3]. To better recreate
natural patterns of plasma insulin kinetics, analogs of insulin
have been developed. Thus, rapid-acting insulin analogs con-
tain minor modifications to the amino acid sequence in re-
gions involved in self-association that are designed to weaken
insulin–insulin binding and accelerate absorption, producing
a kinetic profile similar to the natural prandial response [3].
An example is insulin aspart (B28 aspartic acid human insulin)
in which proline is substituted by aspartic acid at the B28
position.
To recreate the basal level of circulating insulin, several
principles have been applied, all of which serve to increase the
molecular mass/self-association state of the insulin in the
depot. In the case of neutral protamine Hagedorn (NPH)
insulin, the peptide protamine is added to the formulation
causing the insulin to form a crystalline precipitate that dis-
solves after injection [4]. NPH has been widely used, but its
kinetic profile is an imperfect approximation of basal insulin
secretion, with absorption still tending to rise and fall from a
peak concentration (Cmax) value [5–7]. Furthermore, its ab-
sorption rate is rather unpredictable, and this problem is
compounded by the need to re-suspend the precipitate prior
to injection, which patients may not do effectively [8, 9]. Two
soluble insulin analogs improve on this profile. Insulin glargine
(marketed as Lantus® by Sanofi) is presented as a solute in a
slightly acidic formulation, but it precipitates after injection as
pH rises [10]. Insulin detemir (marketed as Levemir® by
Novo Nordisk A/S) features the attachment of a myristic acid
side chain, which enables reversible albumin binding. This,
together with dihexameric self-association, prolongs the ab-
sorption profile [11].
Each of these basal insulin analogs can be used to supple-
ment or recreate physiological basal insulin availability, and
rapid-acting analogs can be given additionally at mealtimes to
supplement or recreate the prandial insulin response. Such
basal–bolus insulin regimens are, however, challenging for
patients as they require multiple daily injections with frequent
blood glucose sampling to ensure optimal dose adjustment.
This is of vital importance in type 1 and advanced type 2
diabetes where the regimen constitutes full insulin-
replacement therapy but, in earlier stages of type 2 diabetes,
simpler, more convenient regimens may suffice and aid
adherence.
A popular option in type 2 diabetes is to use a ‘premixed’
insulin formulation whereby a single injection can be given
with main meals to supplement both prandial and basal
insulin output. Ideally, this would be a mixture of two insulin
analogs designed specifically for these roles, but there are
problems: rapid-acting analogs require neutral formulations
to remain stable, while insulin glargine requires an acidic
formulation to remain soluble; hence, this mixture is consid-
ered incompatible. Indeed, a clamp study has shown that the
pharmacodynamic (PD) profile of insulin lispro is flattened
when combined with glargine [12]. Insulin detemir can be co-
formulated in a neutral environment with other insulins, but
there are self-association equilibriums for these components
that could enable monomers to recombine in hybrid
hexamers. Again, a clamp study has shown that the peaked
PD profile of insulin aspart is attenuated and prolonged when
combined with detemir [13], consistent with hybrid hexamer
formation. Until now, premixed insulin products have there-
fore reverted to the protamination technology used for NPH
insulin. Thus, human insulin or a rapid-acting analog is for-
mulated with sufficient protamine to crystallize a percentage
(e.g., 70%) of the insulin content. This then acts as the basal
component, with the remaining insulin solute absorbing rap-
idly to provide a prandial dose [3]. Unsurprisingly, however,
such products bring with them the kinetic limitations associ-
ated with NPH insulin [8, 14]. Adequate resuspension is
required to ensure dose accuracy, and the absorption kinetics
of the basal component is faster and with more of a peak effect
than would be desired.
Insulin degludec (Nε-hexadecandioyl-γ-Glu-LysB29 desB30
human insulin) is the latest basal insulin analog to be
marketed. It differs from human insulin by deletion of the
B30 threonine and addition by acylation at B29 with a gluta-
mate spacer and 16-carbon fatty diacid side chain. The pro-
traction mechanism involves post-injection formation of long
multihexamer chains from which monomers are slowly re-
leased [15, 16], producing a flat, glucose-lowering action at
steady state, with lower intra-patient day-to-day variability
than insulin glargine [17]. In pharmaceutical formulation, in
the presence of preservatives including phenol, insulin
degludec assembles as dihexamers held together by side
chain–zinc contacts, a structure considered to be highly stable
[15, 16]. It is therefore feasible that insulin degludec could be
combined in solution with a fast-acting insulin such as insulin
aspart without interactions occurring in the formulation. After
injection, phenol diffuses quickly from an insulin injection
depot [11], and this process causes insulin degludec to under-
go the conformational change required to enable
multihexamer formation [15]. If the post-injection formation
of insulin degludec multihexamers and the disassembly of
insulin aspart hexamers were then to be discrete processes,
the individual PK/PD profile of the two insulin analogs
should then be preserved, giving a clearer separation of the
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basal and prandial kinetics than hitherto possible with tradi-
tional premix products. We therefore investigated the associ-
ation states of these insulin analogs (in isolation and co-
formulated) in conditions designed to simulate the pharma-
ceutical formulation and subcutaneous depot to assess the
extent of any interactions between insulin degludec and insu-
lin aspart.
MATERIALS AND METHODS
Insulin degludec was prepared as described earlier [18]. For-
mulations were made by dissolution of insulin degludec
followed by addition of 1.6% glycerol, 16 mM phenol,
16 mM m-cresol, 10 mM sodium chloride, and zinc acetate
so as to create ratios of 3 or 5 Zn ions per 6 insulin monomers
(Zn/6ins). The pH was adjusted to 7.4, and water added to
final volume with an insulin degludec concentration of
0.6 mM.
Insulin aspart and human insulin were obtained at Novo
Nordisk, Denmark. Formulations were made by suspension of
0.6 mM insulin analog and dissolution by addition of diluted
hydrochloric acid followed by zinc acetate to 2 Zn/6ins, 1.6%
glycerol, 16 mM phenol, 16 mM m-cresol, 10 mM sodium
chloride, and pH adjusted to 7.4 by diluted sodium hydroxide.
Formulations of 0.6 mM insulin degludec at 3 and 5 Zn/6ins
were combined with 0.6mM insulin aspart and human insulin
respectively in proportions of 70:30 and stored for 4 weeks at
25°C. For comparison, Levemir® (insulin detemir) was com-
bined with NovoRapid® (insulin aspart) in the same propor-
tions and stored for 4 weeks at 25°C.
SIZE-EXCLUSION CHROMATOGRAPHY
Size-exclusion chromatography (SEC) was performed to char-
acterize the association states for the individual basal and
rapid-acting insulins, and for the combinations. Three SEC
methods were used as in vitro models to simulate conditions in
the pharmaceutical formulation (at high concentration of
phenol and room temperature), the condition in the subcuta-
neous depot after injection (without phenol and at body
temperature) and, finally, to evaluate a serial decrease in
concentration of phenol and m-cresol, as expected to occur
following subcutaneous injection. Furthermore, fractions of
high and lowmolarmass were collected from the SEC eluents,
and reverse-phase chromatography was used to measure the
concentrations of the individual insulin within them.
SEC method 1 was designed to simulate conditions in the
pharmaceutical formulation (with the same phenol concentra-
tion), and was used to measure the percentage of oligomers of
dihexamer, dihexamers, hexamers, and monomers with elu-
ent of 16 mM phenol, 140 mM sodium chloride, 10 mM tris
(hydroxymethyl) aminomethane (tris) pH 7.3, and 0.01%
sodium azide at 23°C. The size-exclusion column used was
ACQUITYUPLC®BEH200 (150*4.6 mm, d=1.7 μm) from
Waters Corporation, Milford, MA, USA. Ultraviolet detec-
tion wavelengths were at 286, 276 and 290 nm for methods 1–
3, respectively. Injection volume was 20 μL and flow was
0.15 mL/min.
SEC method 2 was designed to simulate conditions in the
subcutaneous depot (in which phenol quickly dissipates), and
was used tomeasure the percentage of multihexamer versus the
hexamer–monomer fraction with a phenol-free eluent of
140 mM sodium chloride, 10 mM tris pH 7.3, 0.01% sodium
azide, and 5% 2-propanol at 37°C. The concentrations of the
individual insulin analogs in the multihexamer fraction and
the hexamer–monomer fraction were determined by reverse-
phase chromatography. A SymmetryShield RP18
(3.9*20 mm, d=3.5 μm) column from Waters Corporation
(Milford, MA, USA) was eluted with A: 10%(vol) acetonitrile
0.2 M sodium sulfate, 40 mM o-phosphoric acid adjusted to
pH 3.6 with sodium hydroxide and B: 70%(vol) acetonitrile at
a gradient of 20–54% at 1.4–5 min at 30°C, 1 mL/min, and
detection at 276 nm. To avoid adsorption, 70 ppm polysor-
bate 20 was added to the fraction vials.
For comparison, insulin detemir was combined with insulin
aspart in the same proportions (volume 70:30) and stored for
4 weeks at 25°C. SEC method 2 was modified for the combina-
tion of insulin detemir and insulin aspart by dividing fraction
collection between hexamer and dimer (since insulin detemir
achieves its protracted absorption largely through reversible
albumin binding rather than multihexamer formation).
SEC method 1 was not employed for an insulin detemir
and insulin aspart combination. This is because in the pheno-
lic SEC eluent (similar to the pharmaceutical formulation),
insulin detemir elutes as a hexamer [11, 15], as does insulin
aspart, so the two insulin analogs (and any hybrid associations)
would therefore be indistinguishable using this method.
SECmethod 3 was designed to simulate serial conditions at
decreasing concentrations of the preservatives phenol and m-
cresol, as will occur immediately after subcutaneous injection.
These tests were made by mixing A: 16 mM phenol and m-
cresol , 20 mM sodium chlor ide , 3 mM sodium
dihydrogenphosphate pH 7.3, and 0.01% sodium azide, with
B : 1 40 mM sod i um ch l o r i d e , 3 mM sod i um
dihydrogenphosphate pH 7.3, and 0.01% sodium azide at
37°C. Transformation of insulin degludec dihexamers to
multihexamers, and of insulin aspart hexamers to monomers,
was compared with human insulin.
DYNAMIC LIGHT SCATTERING
Dynamic light scattering (DLS) also provides information
about the molecular size of solutes and was used to validate
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the SEC results by testing the formulations prepared for SEC
method 1. These insulin formulations were expected to con-
tain insulin in various self-association states, hence the ac-
quired hydrodynamic radius for each formulation will be an
average (Rh average). Since the insulin concentration was kept
constant to 0.6 mM in all formulations, the average hydrody-
namic radii are comparable. DLS data were acquired at 25°C
by adding 30 μL of each sample in triplicates to a 384 well
plate Corning® 3540 (Corning, NY, USA). Each well was
measured 20 times with 10 s acquisition time, resulting in 600
measurements for each sample composition. A DynaPro™
Plate Reader and Dynamics™ software version 7.1.8.93 (Wy-
att Technology Corp., Santa Barbara, CA, USA) was used to
collect and analyse the data.
RESULTS
Pharmaceutical Formulation Simulations
Data for the self-association states of the various insulin prep-
arations eluted using SEC method 1 are presented in Table I
and Fig. 1. When formulated with a zinc concentration of 3
Zn/6ins, insulin degludec eluted primarily in a dihexameric
state (91%) with a fraction of hexamers and monomers. When
zinc was increased to 5 Zn/6ins, insulin degludec eluted
mostly as dihexamers or larger structures. Insulin aspart at 2
Zn/6ins eluted as hexamers (88%) and monomers, and hu-
man insulin (at the same zinc concentration) eluted primarily
as hexamers (98%), with the remainder as monomers. For the
combinations of insulin degludec and insulin aspart (prepared
in a 70:30 ratio), the proportions of dihexamer versus
hexamer–monomer were 73:27 and 71:29 at the two insulin
degludec formulation zinc concentrations of 3 and 5 Zn/6ins,
respectively. A similar set of experiments substituting insulin
aspart with human insulin showed proportions of dihexamer
versus hexamer–monomer of 87:13 and 74:26, respectively.
Subcutaneous Depot Simulations
Data for the self-association states of the insulin preparations
eluted using SEC method 2 are presented in Table II and
Fig. 2. Using SEC method 2 (without phenol), insulin
degludec eluted as multihexamers, whereas insulin aspart
was fully monomeric and human insulin eluted below
hexamer size. A high molar mass and a low molar mass
fraction were collected from the eluent (dividing between
dihexamer and hexamer), and the concentrations and pro-
portions of the constituent insulin were determined by reverse-
phase chromatography (Table II). When eluted alone, insulin
degludec primarily appeared in the multihexamer fraction
(91% at 3 Zn/6ins and 99% at 5 Zn/6ins), whereas insulin
aspart and human insulin were only found in the monomer–
hexamer fraction when eluted alone.
The combination of insulin degludec and insulin aspart at
low zinc concentration showed 89% of insulin degludec to be
in the multihexamer fraction and 35% of aspart in the mono-
mer–hexamer fraction. Substituting insulin aspart with hu-
man insulin, the distributions were 92 and 8% respectively. At
the higher zinc concentration, however, 99% of insulin aspart
appeared in the monomer–hexamer fraction, with a similar
proportion of insulin degludec eluting as multihexamers. For
human insulin, 88% appeared in the monomer–hexamer
fraction when combined with insulin degludec in the 5 Zn/
6ins concentration (Table II).
Table I SEC and DLS Simulating Pharmaceutical Formulation (Method 1). Self-Association States for Individual and Combined Insulin Preparations Formulated
with Pharmaceutical Preservatives and Different Zinc (Zn) Concentrations Determined by SEC, with Hydrodynamic Radius (Rh) and Polydispersity Index (PDI)
Determined by DLS. Combined Formulations Included 70% Insulin Degludec and 30% Insulin Aspart or Human Insulin, Stored for 4 weeks at 25°C. DLS Data
on Unperturbed Formulations are Included
Insulin/zinc formulation % eluting as dihexamer
or larger structure in SEC
% eluting as hexamer or
smaller structure in SEC
Rh average in DLS PDI in DLS
Insulin degludec 3 Zn/6ins alone 91 9 3.04±0.06 0.15±0.06
Insulin degludec 5 Zn/6ins alone 100 0 3.15±0.01 0.22±0.01
Insulin aspart 2 Zn/6ins alone 0 100 2.47±0.00 0.24±0.00




















74 26 3.30±0.04 0.22±0.01
DLS, dynamic light scattering; SEC, size-exclusion chromatography
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In the insulin detemir and insulin aspart simulations, insu-
lin detemir, when eluted alone, appeared mainly in a
dihexamer–hexamer fraction (86%), whereas insulin aspart
alone eluted at a size smaller than hexameric (99%). When
insulin detemir and insulin aspart were combined, 82% of
insulin detemir was found in the dihexamer–hexamer frac-
tion, whereas the content of insulin aspart eluting below
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Combination 70:30 insulin degludec:insulin aspart
Fig. 1 SEC simulating
pharmaceutical formulation
(method 1). Elution curves
comparing insulin analogues
eluted alone or in combination,
with insulin degludec formulated
at two different zinc (Zn)
concentrations (n zinc ions per 6
insulin monomers). When mixed
together in a 70:30 ratio, the
proportion of insulin eluting as
dihexamers is increased beyond
70% at the lower (b), but not the
higher (d), zinc concentration. AU,
absorbance unit; SEC, size-
exclusion chromatography.
Table II SEC Simulating Subcutaneous Environment (Method 2). Percentages of Insulin Type Recovered from Eluent Fractions Distinguished by Mass for
Individual and Combined Insulin Preparations Formulated with Pharmaceutical Preservatives and at Different Zinc (Zn) Concentrations. Combined Formulations
Included 70% Insulin Degludec and 30% Insulin Aspart or Human Insulin, Stored for 4 weeks at 25°C. Eluents were Phenol-Free and Warmed to 37°C
Insulin/zinc formulation % of total insulin degludec
eluting in multihexamer fraction
% of total insulin aspart/human insulin
eluting in hexamer or smaller fraction
Insulin degludec 3 Zn/6ins alone 91 –
Insulin degludec 5 Zn/6ins alone 99 –
Insulin aspart 2 Zn/6ins alone – 100
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Simulations of Serial Decrease in Preservative
Concentration
In the SEC method 3 tests, insulin degludec eluted mainly as
dihexamers until the preservative concentration dropped to a
threshold of 0.5 mM phenol and m-cresol, at which point self-
association into multihexamers began to occur (Fig. 3). Insulin
aspart eluted mainly as hexamers when the preservatives were at
a concentration of 8 mM, but it became fully monomeric at the
lower preservative concentration of 2 mM phenol and m-cresol
(Fig. 3). Finally, human insulin remained hexameric at lower
preservative concentrations than insulin aspart, but eluted below
hexameric size when phenol and m-cresol were absent.
Validation of SEC Data by DLS
DLS data are summarized in Table I. Formulations of insulin
degludec with 5 Zn/6ins had a slightly larger average hydro-
dynamic radii (Rh average) compared with 3 Zn/6ins. The Rh
average for insulin aspart and human insulin (2 Zn/6ins) were
smaller than those of insulin degludec and similar to each
other. In the two co-formulations of insulin degludec and
insulin aspart, the Rh average values were almost identical.
The Rh average of the co-formulation with 5 Zn/6 insulin
degludec and human insulin was, on the other hand, signifi-
cantly larger than the formulation containing 3 Zn/6 insulin
degludec and human insulin.
DISCUSSION
The SEC studies simulating the pharmaceutical formulation
show that insulin degludec is primarily self-associated as
dihexamers, with a small monomer fraction at low zinc con-
centrations (3 Zn/6ins) or a minor tetrahexamer content at
high zinc concentration (5 Zn/6ins). These observations are
therefore consistent with earlier SEC studies [15]. In a phar-
maceutical formulation, the short-acting analog, insulin
aspart, and human insulin were shown to be mainly self-
associated as hexamers, but with some monomeric content
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Combination 70:30 insulin degludec:insulin aspart
Insulin degludec alone
Insulin aspart alone
Combination 70:30 insulin degludec:insulin aspart
a Insulin degludec formulated at 3 Zn/6ins c Insulin degludec formulated at 5 Zn/6ins
b Insulin degludec formulated at 3 Zn/6ins d Insulin degludec formulated at 5 Zn/6ins
Fig. 2 SEC simulating depot
environment (method 2). Elution
curves comparing insulin analogs
eluted alone or in combination with
insulin degludec formulated at two
different zinc (Zn) concentrations (n
zinc ions per 6 insulin monomers).
When mixed together in a 70:30
ratio, the proportion of insulin
aspart eluting as monomers is
reduced at the lower zinc
concentration (b) due to
incorporation into multihexamers.
At the higher zinc concentration (d),
insulin aspart elutes almost entirely
in the monomeric fraction, and
insulin degludec elutes in the
multihexameric fraction, which
shows slight leftward shift, indicating
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degludec at a low zinc concentration with insulin aspart (70:30
ratio) showed a dihexamer content that was higher than the
proportion of insulin degludec. This suggests that degludec–
aspart hybrid hexamers (and thereby hybrid dihexamers) were
forming, presumably through the association of free
monomers of insulin degludec and insulin aspart. When hu-
man insulin was combined with insulin degludec, the
dihexamer content was higher still. A combination of insulin
degludec at the high zinc concentration with insulin aspart,
however, showed a dihexamer content corresponding almost
exactly to the proportion of insulin degludec, although an
increased amount of dihexamer was still seen with human
insulin. Generally, an increased zinc concentration induces
increased insulin self-association, but in this experiment the
increase in zinc is actually associated with less dihexamer
formation. The likely explanation is that when degludec is
formulated at higher zinc concentration, monomers are no
longer present, hence degludec–aspart hybrid hexamers can
no longer formwhen insulin aspart is added. These results can
be interpreted as showing that insulin degludec and insulin
aspart can be co-formulated at high zinc concentrations with
little, if any, interaction occurring between the two, provided
insulin aspart is added to fully dihexameric insulin degludec.
With human insulin, however, a co-formulation does still
result in the occurrence of some hybrid self-associations, which
might be explained by the relatively greater tendency for
human insulin to self-associate compared with insulin aspart.
We consider that the DLS data support these interpreta-
tions. Formulations of insulin aspart and human insulin had
Rh average values that were consistent with the hydrodynamic
size of an insulin hexamer at low ionic strength [19, 20],
whereas the insulin degludec formulations had Rh average
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Insulin degludec 5 Zn/6ins
Insulin aspart 2 Zn/6ins
Human insulin 2 Zn/6ins
Fig. 3 SEC simulating depot environment (method 3), with varied pharma-
ceutical preservative concentrations (phenol and m-cresol). The percent of
insulin aspart eluting as hexamers declines quickly as preservative concentra-
tion decreases, while insulin degludec becomes multihexameric only at very
low phenol and m-cresol concentration. SEC, size-exclusion chromatography;
Zn, zinc.
Fig. 4 After injection, insulin
degludec and insulin aspart undergo
different changes. Insulin aspart
hexamers rapidly dissociate into
monomers that are readily
absorbed into the circulation over a
short time. Insulin degludec
dihexamers associate to form
soluble multihexamers from which
monomers are slowly released to
be absorbed into the circulation
over a prolonged time. IAsp, insulin
aspart; IDeg, insulin degludec.
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mainly dihexamers [19]. The polydispersity index (PDI) indi-
cates that species of different sizes are present in solution. The
SEC data show that the co-formulations contain structures
ranging from monomer to>dihexamer size, so the Rh average
values for the co-formulations are difficult to interpret in
detail. For the two insulin aspart plus insulin degludec co-
formulations, however, the similar radii are consistent with the
fact that≥dihexamer:≤ hexamer ratios obtained by SEC were
almost identical. The co-formulation with 3 Zn/6 insulin
degludec and human insulin had a smaller Rh average than
the formulation containing 5 Zn/6 insulin degludec and hu-
man insulin. Hence, the size distribution appears to be shifted
towards larger species. This might seem to contradict the SEC
results (Table I) where the fraction eluting as≤hexamer is
increased, while the fraction eluting as≥dihexamer is de-
creased as we move from 3 to 5 Zn/6 insulin degludec; if a
larger fraction of≤hexamer and a smaller fraction with spe-
cies≥dihexamer are formed, then intuitively the expectation is
of a decrease in overall average size. However, this expecta-
tion is based on the assumption that the internal size distribu-
tion of the two fractions remains identical. In fact, as explained
above (and illustrated in Fig. 1) an increased zinc concentra-
tion will result in the increased association of monomers and
dimers into hexamers, and furthermore, dihexamers start to
associate as tetrahexamers (more pronounced for the degludec
and human insulin co-formulation). Therefore, the Rh average
of the overall value is increased.
The subcutis simulations were designed to test whether
interactions can still occur between the different insulin com-
ponents following injection. Eluting each individual insulin
alone showed the self-association state it would naturally
adopt with the dissipation of preservatives. Consistent with
previous research [15, 16], insulin degludec eluted primarily
as high-mass multihexameric complexes, while insulin aspart
eluted in a monomer–hexamer fraction. When insulin
degludec and insulin aspart were combined in a low zinc
concentration, only 35% of the insulin aspart eluted in the
monomer–hexamer fraction, implying that much of it was
being incorporated into the multihexamer complexes and/
or that hybrid dihexamers were again forming. This was also
true for human insulin. When a higher zinc concentration was
used, however, the interaction between insulin degludec and
insulin aspart again disappeared, while the interaction be-
tween insulin degludec and human insulin was diminished.
Interestingly, in the insulin degludec and insulin aspart com-
bination with high zinc, the elution curve for insulin
degludec was shifted slightly to the left, implying the
formation of larger multihexamer complexes (Fig. 2d). A
possible explanation for this observation is that the
additional zinc ions liberated from dissociated insulin
aspart hexamers enable insulin degludec to form into
larger multihexamer units, since zinc binding is a char-
acteristic of hexameric but not of monomeric insulin.
Insulin detemir was also studied alone and in combination
with insulin aspart and these studies showed clear differences
between the self-association states when the two insulin ana-
logs were eluted alone compared with when they were com-
bined. In the latter situation, the percentage of insulin aspart
eluting in the monomer–hexamer fraction decreased from 99
to 64%, implying that about a third of the insulin aspart was
associating into dihexameric structures with insulin detemir.
The serial (method 3) SEC study, with diminishing con-
centrations of preservatives, was designed to examine the
relative time frames over which insulin degludec would adopt
a multihexamer self-association state, and insulin aspart and
human insulin would become monomeric. The relevance of
this is that, as part of the process of forming multihexamer
chains, insulin degludec hexamers undergo a conformational
change (as phenol dissipates) whereby both poles of the
hexamer open to allow linkage between a zinc ion in the core
of one hexamer and a fatty diacid side chain of another
hexamer [15, 16]. At this point in the linking process, it would
be theoretically possible for hexamers of another insulin to be
incorporated into the multihexamer chains as a result of
interactions between their zinc ions and insulin degludec side
chains. However, our studies showed that insulin aspart be-
comes completely monomeric at a higher preservative con-
centration than that at which insulin degludec begins to form
multihexamers. This was not true, however, for human
insulin.
Therefore, the subcutaneous simulations collectively show
that, in the high zinc concentration formulation, the self-
association state kinetics of insulin degludec and insulin aspart
will take place independently of each other after injection
(Fig. 4). In contrast, there is a degree of interaction between
insulin degludec and human insulin.
CONCLUSION
Our studies collectively demonstrate how hybrid insulin asso-
ciations can form when different insulin molecules are co-
formulated, especially at lower zinc concentrations, and also
how hybrid associations can form in conditions that simulate
the subcutaneous depot. This problem has hitherto prevented
the co-formulation of two different insulin analogs that have
distinct and desired PK/PD profiles (e.g., insulin detemir and
insulin aspart) because these profiles would have been com-
promised by such interactions. Therefore, ‘premix’ insulin
analog products have all been based on partial protamination
of a rapid-acting insulin. However, our studies have also
shown that at the high zinc concentration used in the phar-
maceutical formulation, insulin degludec and insulin aspart do
not interact in conditions that simulate either the formulation
or the subcutaneous depot. Furthermore, the serial SEC study
suggests that the two processes of insulin aspart hexamer
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dissociation and insulin degludecmultihexamer formation will
occur sequentially and separately, thereby preventing another
potential interaction. These studies therefore predict that the
discrete PK/PD profiles of insulin degludec and insulin aspart
would be preserved in a high zinc co-formulation, and this
expectation has indeed been borne out in a clamp study [14],
and in clinical studies of the combination product, as evi-
denced by clinical advantages over traditional premixed insu-
lin regimens [21–23]. In summary, our experiments provide a
molecular-level model for understanding how this particular
combination of insulin analogs succeeds clinically.
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